← All trials
NCT07174427
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2025
- Primary completion
- Mar 31, 2032
- Completion date
- Mar 31, 2032
- First posted
- Sep 16, 2025
- Last posted
- Sep 16, 2025
- Enrollment
- 5
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Takara Bio Inc.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.